Results 1 to 10 of about 240,902 (118)

Lipoprotein metabolism indicators improve cardiovascular risk prediction. [PDF]

PLoS ONE, 2014
BACKGROUND: Cardiovascular disease risk increases when lipoprotein metabolism is dysfunctional. We have developed a computational model able to derive indicators of lipoprotein production, lipolysis, and uptake processes from a single lipoprotein profile
Daniël B van Schalkwijk, Albert A de Graaf, Evgeni Tsivtsivadze, Laurence D Parnell, Bianca J C van der Werff-van der Vat, Ben van Ommen, Jan van der Greef, José M Ordovás   +7 more
doaj   +3 more sources

A computational model for the analysis of lipoprotein distributions in the mouse: translating FPLC profiles to lipoprotein metabolism.

PLoS Computational Biology, 2014
Disturbances of lipoprotein metabolism are recognized as indicators of cardiometabolic disease risk. Lipoprotein size and composition, measured in a lipoprotein profile, are considered to be disease risk markers.
Fianne L P Sips, Christian A Tiemann, Maaike H Oosterveer, Albert K Groen, Peter A J Hilbers, Natal A W van Riel   +5 more
doaj   +3 more sources

A Simple Fluorescent Cholesterol Labeling Method to Cryoprotect and Detect Plasma Lipoprotein-X

Biology, 2022
Lipoprotein-X (LpX) are abnormal nephrotoxic lipoprotein particles enriched in free cholesterol and phospholipids. LpX with distinctive lipid compositions are formed in patients afflicted with either familial LCAT deficiency (FLD) or biliary cholestasis.
Edward B. Neufeld, Lita A. Freeman, Vinay Durbhakula, Maureen L. Sampson, Robert D. Shamburek, Sotirios K. Karathanasis, Alan T. Remaley   +6 more
doaj   +1 more source

Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases

Cells, 2021
Since the seminal breakthrough of treating diabetic patients with insulin in the 1920s, there has been great interest in developing other proteins and their peptide mimetics as therapies for a wide variety of other medical disorders. Currently, there are
Anna Wolska, Mart Reimund, Denis O. Sviridov, Marcelo J. Amar, Alan T. Remaley   +4 more
doaj   +1 more source

Short hydrocarbon stapled ApoC2-mimetic peptides activate lipoprotein lipase and lower plasma triglycerides in mice

Frontiers in Cardiovascular Medicine, 2023
IntroductionDefects in lipolysis can lead to hypertriglyceridemia, which can trigger acute pancreatitis and is also associated with cardiovascular disease.
Denis Sviridov, Amaury Dasseux, Mart Reimund, Milton Pryor, Steven K. Drake, Zack Jarin, Anna Wolska, Richard W. Pastor, Alan T. Remaley   +8 more
doaj   +1 more source

A new phenotypic classification system for dyslipidemias based on the standard lipid panel

Lipids in Health and Disease, 2021
Highlights A new algorithm is described for categorizing dyslipidemic patients into Fredrickson-like lipoprotein phenotypes except for Type III. The new lipoprotein phenotypes were validated by NMR-lipoprotein analysis and by agarose gel electrophoresis ...
Maureen Sampson, Rami A. Ballout, Daniel Soffer, Anna Wolska, Sierra Wilson, Jeff Meeusen, Leslie J. Donato, Erica Fatica, James D. Otvos, Eliot A. Brinton, Robert S. Rosenson, Peter Wilson, Marcelo Amar, Robert Shamburek, Sotirios K. Karathanasis, Alan T. Remaley   +15 more
doaj   +1 more source

Transgelin: a new gene involved in LDL endocytosis identified by a genome-wide CRISPR-Cas9 screen

Journal of Lipid Research, 2022
A significant proportion of patients with elevated LDL and a clinical presentation of familial hypercholesterolemia do not carry known genetic mutations associated with hypercholesterolemia, such as defects in the LDL receptor.
Diego Lucero, Ozan Dikilitas, Michael M. Mendelson, Zahra Aligabi, Promotto Islam, Edward B. Neufeld, Aruna T. Bansal, Lita A. Freeman, Boris Vaisman, Jingrong Tang, Christian A. Combs, Yuesheng Li, Szilard Voros, Iftikhar J. Kullo, Alan T. Remaley   +14 more
doaj   +1 more source

Apolipoprotein distribution in human lipoproteins separated by polyacrylamide gradient gel electrophoresis.

Journal of Lipid Research, 1988
The heterogeneity of serum lipoproteins (excluding very low density (VLDL) and intermediate density (IDL) lipoproteins) and that of lipoproteins secreted by HepG2 cells has been studied by immunoblot analysis of the apolipoprotein composition of the ...
C A Vézina, R W Milne, P K Weech, Y L Marcel   +3 more
doaj   +1 more source

Nonimmunochemical quantitation of mammalian apolipoprotein A-I in whole serum or plasma by nonreducing gel electrophoresis.

Journal of Lipid Research, 1989
A rapid and convenient method for the quantitation of mammalian apoA-I has been developed. The method involves nonreducing sodium dodecyl sulfate gel electrophoresis and Coomassie blue staining, and takes advantage of the relative abundance of apoA-I in ...
D S France, T E Hughes, R Miserendino, J A Spirito, J Babiak, J B Eskesen, C Tapparelli, J R Paterniti, Jr   +7 more
doaj   +1 more source

An immunochemical marker of low density lipoprotein oxidation.

Journal of Lipid Research, 1989
Using monoclonal antibodies against apolipoprotein B (apoB) we studied changes in apoB immunoreactivity during copper ion-mediated oxidation of human low density lipoprotein (LDL).
Z Zawadzki, R W Milne, Y L Marcel
doaj   +1 more source